PURPOSE: Despite decades of research, consensus on optimal treatment for pancreatic cancer has not been reached and survival remains bleak. This study aimed to evaluate predictors of treatment and survival among patients treated in community settings. METHODS: A sample of pancreatic cancer patients who were diagnosed in 2009 and reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program (n = 977) was included. Logistic regression was used to assess factors associated with therapy modality. Survival was examined using the Kaplan-Meier method and Cox proportional hazards regression. All analyses were conducted stratified by tumor stage. RESULTS: Among stages I-II patients, 27 % received no treatment and only 47 % received surgery. Among these patients, no treatment was associated with older age, being a woman, not being married, lower income, and larger or unknown tumor size. Additionally, the type of adjuvant therapy received varied by tumor characteristics, race/ethnicity, and socioeconomic status. The most common therapies for stage III tumors were chemoradiation (40.8 %) and chemotherapy (21.9 %) alone. Half of stage IV patients received chemotherapy; chemotherapy was less common in patients who were older, in a minority race/ethnicity, and not married. Although treatment was associated with better prognosis, even among stages I-II patients who underwent surgery, a quarter succumbed to their disease within 17 months. CONCLUSION: A significant proportion of pancreatic cancer patients remain undertreated primarily due to nonclinical factors, including marital status. Further investigating what aspects of marriage are contributing to this association will provide a better understanding of pancreatic cancer treatment barriers.
PURPOSE: Despite decades of research, consensus on optimal treatment for pancreatic cancer has not been reached and survival remains bleak. This study aimed to evaluate predictors of treatment and survival among patients treated in community settings. METHODS: A sample of pancreatic cancerpatients who were diagnosed in 2009 and reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program (n = 977) was included. Logistic regression was used to assess factors associated with therapy modality. Survival was examined using the Kaplan-Meier method and Cox proportional hazards regression. All analyses were conducted stratified by tumor stage. RESULTS: Among stages I-II patients, 27 % received no treatment and only 47 % received surgery. Among these patients, no treatment was associated with older age, being a woman, not being married, lower income, and larger or unknown tumor size. Additionally, the type of adjuvant therapy received varied by tumor characteristics, race/ethnicity, and socioeconomic status. The most common therapies for stage III tumors were chemoradiation (40.8 %) and chemotherapy (21.9 %) alone. Half of stage IV patients received chemotherapy; chemotherapy was less common in patients who were older, in a minority race/ethnicity, and not married. Although treatment was associated with better prognosis, even among stages I-II patients who underwent surgery, a quarter succumbed to their disease within 17 months. CONCLUSION: A significant proportion of pancreatic cancerpatients remain undertreated primarily due to nonclinical factors, including marital status. Further investigating what aspects of marriage are contributing to this association will provide a better understanding of pancreatic cancer treatment barriers.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Jessica P Simons; Sing Chau Ng; Theodore P McDade; Zheng Zhou; Craig C Earle; Jennifer F Tseng Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: R Casadei; N Zanini; A M Morselli-Labate; L Calculli; R Pezzilli; O Potì; T Grottola; C Ricci; F Minni Journal: World J Surg Date: 2006-11 Impact factor: 3.352
Authors: Steven J Cohen; Ralph Dobelbower; Stuart Lipsitz; Paul J Catalano; Benjamin Sischy; Thomas J Smith; Daniel G Haller Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Melissa M Murphy; Jessica P Simons; Joshua S Hill; Theodore P McDade; Sing Chau Ng; Giles F Whalen; Shimul A Shah; Lynn H Harrison; Jennifer F Tseng Journal: Cancer Date: 2009-09-01 Impact factor: 6.860
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Marsha Reyngold; Kathryn A Winter; William F Regine; Ross A Abrams; Howard Safran; John P Hoffman; Rex B Mowat; John P Hayes; Ivan L Kessel; Thomas DiPetrillo; Samir Narayan; Yuhchyau Chen; Edgar Ben-Josef; Guila Delouya; John H Suh; Joshua Meyer; Michael G Haddock; Marvin Feldman; Rakesh Gaur; Kathleen Yost; Richard A Peterson; David L Sherr; Jennifer Moughan; Christopher H Crane Journal: Oncologist Date: 2019-12-16
Authors: Marsha Reyngold; Kathryn A Winter; William F Regine; Ross A Abrams; Howard Safran; John P Hoffman; Rex B Mowat; John P Hayes; Ivan L Kessel; Thomas DiPetrillo; Samir Narayan; Yuhchyau Chen; Edgar Ben-Josef; Guila Delouya; John H Suh; Joshua Meyer; Michael G Haddock; Marvin Feldman; Rakesh Gaur; Kathleen Yost; Richard A Peterson; David L Sherr; Jennifer Moughan; Christopher H Crane Journal: Oncologist Date: 2019-12-16
Authors: Dana Hashim; Zeinab Farhat; Sylvan Wallenstein; Marta Manczuk; Randall F Holcombe; Lorna Thorpe; Maria J Schymura; Roberto G Lucchini; Paolo Boffetta Journal: Eur J Cancer Prev Date: 2016-07 Impact factor: 2.497
Authors: Vasilios Karavasilis; Epaminontas Samantas; Georgia-Angeliki Koliou; Anna Kalogera-Fountzila; George Pentheroudakis; Ioannis Varthalitis; Helena Linardou; Grigorios Rallis; Maria Skondra; Georgios Papadopoulos; George Papatsibas; Joseph Sgouros; Athina Goudopoulou; Konstantine T Kalogeras; Christos Dervenis; Dimitrios Pectasides; George Fountzilas Journal: Target Oncol Date: 2018-12 Impact factor: 4.493